ASCIMINIB, ASCIMINIB HYDROCHLORIDE, Asciminib
CABL001I12201
Phase 2 small_molecule active
Quick answer
ASCIMINIB, ASCIMINIB HYDROCHLORIDE, Asciminib for Pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), previously treated with one or more tyrosine kinase inhibitors is a Phase 2 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), previously treated with one or more tyrosine kinase inhibitors
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active